Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?

Bone

Volumn 41, Issue 3, 2007, Pages 318-320

  Reid, Ian R ^a   Bolland, Mark J ^a   Grey, Andrew B ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Alendronate; Pamidronate; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; GERANYLTRANSFERASE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BIOACCUMULATION; BONE NECROSIS; BONE RESECTION; BONE TURNOVER; CONCENTRATION RESPONSE; DENTURE; DRUG ACCUMULATION; DRUG EFFECT; DRUG MEGADOSE; EDITORIAL; GASTROINTESTINAL TOXICITY; HUMAN; IN VITRO STUDY; INVASIVE PROCEDURE; JAW DISEASE; MOUTH DISEASE; MOUTH MUCOSA; NONHUMAN; OSTEOPOROSIS; SOFT TISSUE DISEASE; SUPERINFECTION; TREATMENT DURATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW; JAW DISEASES; MOUTH MUCOSA; OSTEONECROSIS;

EID: 34547612321     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.04.196     Document Type: Editorial

References (12)

1. de Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., et al. Esophagitis associated with the use of alendronate. N Engl J Med 335 (1996) 1016-1021
2. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
3. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
4. Hoff A.O., Toth B.B., Altundag K., Guarneri V., Adamus A., Nooka A.K., et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 24 (2006) 8528 [suppl]
5. Hansen T., Kunkel M., Weber A., and Kirkpatrick C.J. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35 (2006) 155-160
6. Moreira M.S., Katayama E., Bombana A.C., and Marques M.M. Cytotoxicity analysis of alendronate on cultured endothelial cells and subcutaneous tissue. A pilot study. Dental Traumatol 21 (2005) 329-335
7. Reszka A.A., Halasy-Nagy J., and Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59 (2001) 193-202
8. Rubegni P., and Fimiani M. Bisphosphonate-associated contact stomatitis. N Engl J Med 355 (2006) E25--E25
9. Reid I.R., Brown J.P., Burckhardt P., Horowitz Z., Richardson P., Trechsel U., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346 (2002) 653-661
10. Baron R., Saffar J.L., and Duflot-Vignery A. Alveolar bone remodelling in the rat: normal status and effects of PTX and PTH on the remodelling sequence and the osteoclastic pool. Calcif Tissue Res 22 (1977) 502-504 [Suppl]
11. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296 (2001) 235-242
12. Polizzotto M.N., Cousins V., and Schwarer A.P. Bisphosphonate-associated osteonecrosis of the auditory canal. Brit J Haematol 132 (2006) 114